Searched for: in-biosketch:yes
person:atturm01
Gene mining and functional genomics in human osteoarthritis
Attur, MG; Dave, MN; Amin, AR
SCOPUS:0037302007
ISSN: 1389-2029
CID: 564072
Differential expression of novel secretory phospholipase A2 enzymes in osteoarthritic and normal human chondrocytes [Meeting Abstract]
Bingham, CO; Reddy, S; Attur, M; Amin, A; Abramson, SB
ISI:000178421800543
ISSN: 0004-3591
CID: 55552
Regulation of cytosolic COX-2 and prostaglandin E2 production by nitric oxide in activated murine macrophages [Meeting Abstract]
Patel, RN; Attur, MG; Dave, MN; Abramson, SB; Amin, AR
ISI:000086643101279
ISSN: 0892-6638
CID: 54643
Gene discovery and functional genomics in human osteoarthritis: Upregulation of osteopontin in human-osteoarthritis affected cartilage and regulation of of nitric oxide and prostaglandin E2 [Meeting Abstract]
Attur, MG; Dave, MN; Stuchin, SA; Kowalski, AS; Lopez, CA; Zhang, J; Abramson, SB; Denhardt, DT; Amin, AR
ISI:000086643101410
ISSN: 0892-6638
CID: 54644
Functional genomic analysis in arthritis-affected cartilage: Yin-yang regulation of inflammatory mediators by a5bl and avb3 [Meeting Abstract]
Attur, MG; Dave, MN; Clancy, RM; Patel, IR; Abramson, SB; Amin, AR
ISI:000086643101413
ISSN: 0892-6638
CID: 54645
A novel mechanism of action of chemically modified tetracyclines (CMTS): inhibition of COX-2 mediated PGE2 production [Meeting Abstract]
Attur, MG; Patel, RN; Dave, MN; Patel, IV; Abramson, SB; Amin, AR
ISI:000086643100982
ISSN: 0892-6638
CID: 54640
Tetracycline upregulates COX-2 expression and PGE2 production independent of its effect on nitric oxide [Meeting Abstract]
Attur, MG; Patel, RN; Patel, PD; Abramson, SB; Amin, AR
ISI:000086643101277
ISSN: 0892-6638
CID: 54642
Model protocol to study pharmacogenomics in inflammatory diseases: Human rheumatoid arthritis
Attur, M; Bingham, CO; Dave, M; Abramson, SB; Amin, AR
Pharmacogenomics is a revolution in molecular medicine, especially in view of the development of microarray technologies and proteomics to monitor gene and protein expression. The ability to monitor up to 60,000 potential parameters in a clinical setting gives a whole new meaning to 1) toxic effects, 2) side effects, 3) primary and secondary targets, and il) drug resistance and nonresponders during a clinical trial. Pharmacogenomics may set a new standard to monitor the effects of drugs such as NSAIDS or disease-modifying drugs in diseases such as arthritis. The present article outlines a pharmacogenomics clinical protocol that is in progress, a study that will address some of the above questions. (C) 2000 Wiley-Liss, Inc
ISI:000086020500005
ISSN: 0272-4391
CID: 54733
Localization and regulation of COX-2 by nitric oxide in activated murine macrophages [Meeting Abstract]
Amin, A; Attur, M; Dave, M; Abramson, S
ISI:000076215600666
ISSN: 0004-3591
CID: 53739
Tetracyclines upregulate COX-2 expression and PGE(2) production independently from the inhibition of nitric oxide [Meeting Abstract]
Arnin, AR; Patel, RN; Attur, MG; Patel, PD; Abramson, SB
ISI:000076215601857
ISSN: 0004-3591
CID: 53749